Barclays Increases Edwards Lifesciences (NYSE:EW) Price Target to $101.00

Edwards Lifesciences (NYSE:EW) had its price objective hoisted by equities research analysts at Barclays from $100.00 to $101.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. Barclays‘s price target indicates a potential upside of 18.70% from the company’s previous close.

A number of other brokerages also recently weighed in on EW. Mizuho increased their price objective on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Morgan Stanley upped their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Evercore ISI dropped their target price on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday, April 26th. Finally, Royal Bank of Canada upped their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $93.27.

Edwards Lifesciences Stock Performance

Shares of EW opened at $85.09 on Tuesday. Edwards Lifesciences has a 12 month low of $60.57 and a 12 month high of $96.12. The business’s fifty day simple moving average is $90.05 and its two-hundred day simple moving average is $79.69. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The company has a market cap of $51.28 billion, a price-to-earnings ratio of 36.68, a P/E/G ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Research analysts anticipate that Edwards Lifesciences will post 2.77 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total transaction of $944,130.00. Following the sale, the vice president now owns 39,503 shares in the company, valued at $3,390,542.49. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, VP Donald E. Bobo, Jr. sold 11,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the sale, the vice president now directly owns 39,503 shares of the company’s stock, valued at $3,390,542.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $86.67, for a total value of $2,543,764.50. Following the completion of the sale, the director now owns 4,486 shares in the company, valued at $388,801.62. The disclosure for this sale can be found here. Insiders sold a total of 230,693 shares of company stock valued at $20,310,942 over the last 90 days. Company insiders own 1.27% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently made changes to their positions in EW. Riverview Trust Co purchased a new position in Edwards Lifesciences in the first quarter worth about $34,000. DSM Capital Partners LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth about $34,000. Rise Advisors LLC grew its holdings in Edwards Lifesciences by 125.0% during the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 265 shares during the last quarter. Finally, Pingora Partners LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth about $38,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.